Ferritin in glioblastoma.


Journal

British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635

Informations de publication

Date de publication:
05 2020
Historique:
received: 22 07 2019
accepted: 04 03 2020
revised: 27 02 2020
pubmed: 24 3 2020
medline: 23 12 2020
entrez: 24 3 2020
Statut: ppublish

Résumé

Elevated levels of serum ferritin (SF) are observed in several types of cancer; however, little is known on the association between ferritin and glioma, the most frequent type of human primary brain tumour. Here we report that GBM patients show significantly increased pre-surgical SF levels (i.e. ferritinaemia) within the SF reference range and a marked ferritin immunoreactivity of resected tumour tissue. Our findings account for an indirect association between ferritin synthesis in glioma-tissue and altered SF levels, which limits the clinical value of SF as a tumour marker in glioma. Importantly, we show for the first time that GBM-derived glioma cells release ferritin in vitro, which exerts an apoptosis-stimulating activity. Albeit the pathophysiologic context of apoptosis induction by a tumour-derived ferritin remains to be defined, our findings account for a distinct growth-regulatory role of these ferritin species in tumour biology.

Identifiants

pubmed: 32203223
doi: 10.1038/s41416-020-0808-8
pii: 10.1038/s41416-020-0808-8
pmc: PMC7217840
doi:

Substances chimiques

Biomarkers, Tumor 0
Ferritins 9007-73-2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1441-1444

Références

Wang, W., Knovich, M. A., Coffman, L. G., Torti, F. M. & Torti, S. V. Serum ferritin: past, present and future. Biochim. Biophys. Acta 1800, 760–769 (2010).
doi: 10.1016/j.bbagen.2010.03.011
Cheepsunthorn, P., Palmer, C. & Connor, J. R. Cellular distribution of ferritin subunits in postnatal rat brain. J. Comp. Neurol. 400, 73–86 (1998).
doi: 10.1002/(SICI)1096-9861(19981012)400:1<73::AID-CNE5>3.0.CO;2-Q
Lotz J., Hafner G. & Prellwitz W. Reference values for a homogeneous ferritin assay and traceability to the 3rd International Recombinant Standard for Ferritin (NIBSC Code 94/572). Clin. Chem. Lab. Med. 37, 821–825 (1999).
Liu, Y. F., Li, Q., Yang, P., Wang, W. L. & Liu, J. A. Ferritin in astrocytomas. Chin. Med J. (Engl.) 104, 326–329 (1991).
Schwartzbaum, J. A. & Cornwell, D. G. Oxidant stress and glioblastoma multiforme risk: serum antioxidants, gamma-glutamyl transpeptidase, and ferritin. Nutr. Cancer 38, 40–49 (2000).
doi: 10.1207/S15327914NC381_7
Sato, Y., Honda, Y., Asoh, T., Oizumi, K., Ohshima, Y. & Honda, E. Cerebrospinal fluid ferritin in glioblastoma: evidence for tumor synthesis. J. Neuro-Oncol. 40, 47–50 (1998).
doi: 10.1023/A:1006078521790
Spiegl-Kreinecker, S., Pirker, C., Marosi, C., Buchroithner, J., Pichler, J., Silye, R. et al. Dynamics of chemosensitivity and chromosomal instability in recurrent glioblastoma. Br. J. Cancer 96, 960–969 (2007).
doi: 10.1038/sj.bjc.6603652
Bresgen, N., Rolinek, R., Hochleitner, E., Lottspeich, F. & Eckl, P. M. Induction of apoptosis by a hepatocyte conditioned medium. J. Cell Physiol. 198, 452–60. (2004).
doi: 10.1002/jcp.10439
Bresgen, N., Ohlenschlager, I., Fiedler, B., Wacht, N., Zach, S., Dunkelmann, B. et al. Ferritin-a mediator of apoptosis? J. Cell Physiol. 212, 157–164 (2007).
doi: 10.1002/jcp.21009
Wu, T., Li, Y., Liu, B., Zhang, S., Wu, L., Zhu, X. et al. Expression of ferritin light chain (FTL) Is elevated in glioblastoma, and FTL silencing inhibits glioblastoma cell proliferation via the GADD45/JNK pathway. PLoS ONE. 11, e0149361 (2016).
doi: 10.1371/journal.pone.0149361
Schonberg David, L., Miller Tyler, E., Wu, Q., Flavahan William, A., Das Nupur, K., Hale James, S. et al. Preferential iron trafficking characterizes glioblastoma stem-like cells. Cancer Cell. 28, 441–55. (2015).
doi: 10.1016/j.ccell.2015.09.002
Bresgen, N., Jaksch, H., Lacher, H., Ohlenschläger, I., Uchida, K. & Eckl, P. M. Iron mediated oxidative stress plays an essential role in ferritin induced cell death. Free Radic. Biol. Med. 48, 1347–57. (2010).
doi: 10.1016/j.freeradbiomed.2010.02.019
Sarkaria, J. N., Hu, L. S., Parney, I. F., Pafundi, D. H., Brinkmann, D. H., Laack, N. N. et al. Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data. Neuro-Oncol. 20, 184–91. (2018).
doi: 10.1093/neuonc/nox175
Schneider, S. W., Ludwig, T., Tatenhorst, L., Braune, S., Oberleithner, H., Senner, V. et al. Glioblastoma cells release factors that disrupt blood-brain barrier features. Acta Neuropathologica. 107, 272–276 (2004).
doi: 10.1007/s00401-003-0810-2
Cozzi, A., Levi, S., Bazzigaluppi, E., Ruggeri, G. & Arosio, P. Development of an immunoassay for all human isoferritins, and its application to serum ferritin evaluation. Clin. Chim. Acta 184, 197–206 (1989).
doi: 10.1016/0009-8981(89)90052-1
Tontsch, U. & Bauer, H. C. Isolation, characterization, and long-term cultivation of porcine and murine cerebral capillary endothelial cells. Microvascular Res. 37, 148–61. (1989).
doi: 10.1016/0026-2862(89)90034-4

Auteurs

Heidi Jaksch-Bogensperger (H)

Department of Biosciences, University of Salzburg, Hellbrunnerstrasse 34, Salzburg, A-5020, Austria.
Department of Obstetrics and Gynaecology, Salzburger Landeskliniken (SALK), Paracelsus Medical University Salzburg (PMU), Clinical Research Center, Salzburg, A-5020, Austria.
University Hospital of Neurology, Christian-Doppler-Klinik, Salzburger Landeskliniken (SALK), Paracelsus Medical University Salzburg (PMU), Salzburg, A-5020, Austria.

Sabine Spiegl-Kreinecker (S)

Department of Neurosurgery, Kepler University Hospital GmbH, Johannes Kepler University, Linz, A-4020, Austria.

Paolo Arosio (P)

Laboratory of Molecular Biology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, I-25123, Italy.

Peter Eckl (P)

Department of Biosciences, University of Salzburg, Hellbrunnerstrasse 34, Salzburg, A-5020, Austria.

Stefan Golaszewski (S)

University Hospital of Neurology, Christian-Doppler-Klinik, Salzburger Landeskliniken (SALK), Paracelsus Medical University Salzburg (PMU), Salzburg, A-5020, Austria.

Yvonne Ebner (Y)

University Hospital of Neurology, Christian-Doppler-Klinik, Salzburger Landeskliniken (SALK), Paracelsus Medical University Salzburg (PMU), Salzburg, A-5020, Austria.

Rahman Al-Schameri (R)

Department of Neurosurgery, Christian Doppler Klinik, Salzburger Landeskliniken (SALK), Paracelsus Medical University Salzburg (PMU), Salzburg, A-5020, Austria.

Peter Strasser (P)

Institute for Medical and Chemical Laboratory Diagnostics, Salzburger Landeskliniken (SALK), Paracelsus Medical University Salzburg (PMU), Salzburg, A-5020, Austria.

Serge Weis (S)

Department of Neuropathology, Kepler University Hospital GmbH, Johannes Kepler University, Linz, A-4020, Austria.

Nikolaus Bresgen (N)

Department of Biosciences, University of Salzburg, Hellbrunnerstrasse 34, Salzburg, A-5020, Austria. nikolaus.bresgen@sbg.ac.at.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH